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Styczynski et al. [1] present an EBMT database analysis on 
Epstein-Barr virus (EBV)-related transplant outcomes in a cohort of 
patients with non-malignant disorders. The present paper is the third 
in a row, with the two previous papers demonstrating an association 
between EBV serostatus and development of graft-versus-host 
disease (GVHD) in individuals allografted with acute leukemia and 
lymphoma or chronic malignancy [2, 3]. The vast majority of the 
world’s population remains in a lifelong state of chronic persistent EBV 
infection. During the complex lifecycle of the virus and its prolonged 
co-existence with the human immune system, numerous interactions 
will occur. Across this process, viral antigens exert a significant impact 
on function of certain B-, T- and NK-cell subsets, resulting both in 
immune activation and immune evasion to preclude the complete 
clearance of the virus. In the allogeneic stem cell transplant setting, 
posttransplant lymphoproliferative disorder (PTLD) is the most well-
studied complication associated with EBV [4]. In addition to that, it 
can also be postulated that the presence of EBV (donor and recipient 
serostatus) may have a profound impact on other immune mediated 
occurrences, most notably GVHD. To date, the methods to control 
EBV are rather limited in number. B-cell depletion with rituximab as 
well as adoptive transfer using EBV-specific cytotoxic T-cells are 
feasible methods; however, the efficacy of certain antiviral drugs is yet 
under investigation. It also remains to be proven whether these efforts 
would be sufficient to prevent or ameliorate GVHD. Undoubtedly, 
selecting EBV-negative donors could be an appealing and pragmatic 
option, rendering antiviral therapies unnecessary. Given the high 
seroprevalence of EBV in general population, this approach still does 
not seem to be applicable in real life clinical practice. In the future, well-
designed prospective clinical trials are warranted to study the impact of 
EBV management on transplant outcomes, especially chronic GVHD.
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